Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Victor Lien
03.05.26 -- Phase-Appropriate Control Lessons For mAb/ADC Manufacturers
Next-Level Cell Lines: Bridging Digital Tech With Biologic Innovation See how AI-driven tools and optimized platforms are accelerating biologics development, delivering high-titer clones in weeks, and paving the way for integrated design of cell lines and genetic systems. Improving specific productivity moves the goal beyond pumping out higher titers, but it demands a deeper understanding of cellular biology and protein expression.
02.23.26 -- From Biology Grad To Manufacturing Guru
Webinar: Beyond Standard Approaches: Integrated Thinking for Complex FIH Programs Platform approaches can speed standard programs, but complex molecules demand deeper, integrated thinking. In this KBI webinar, experts share real-world First-in-Human examples where cross-functional collaboration, early holistic decision-making, and downstream insight transformed technical challenges into innovation opportunities.
Real-World Phase-Appropriate Control Lessons For mAb/ADC Manufacturers Original
By Victor Lien, Ph.D., PMP Biologics manufacturing is a balancing act between speed and certainty, innovation and control. For mAbs and antibody-drug conjugates (ADCs), the stakes are especially high: these therapies are complex, sensitive to process variation, and increasingly central to modern medicine. Over the years, I’ve seen how even the most elegant platform can falter without a control strategy that evolves with the molecule.
Real-World Phase-Appropriate Control Lessons For mAb/ADC Manufacturers
By Victor Lien, Ph.D., PMP Biologics manufacturing is a balancing act between speed and certainty, innovation and control. For mAbs and antibody-drug conjugates (ADCs), the stakes are especially high: these therapies are complex, sensitive to process variation, and increasingly central to modern medicine. Over the years, I’ve seen how even the most elegant platform can falter without a control strategy that evolves with the molecule.
01.28.26 -- Manufacturing Complexities Stymie In Vivo Progress
Webinar: The mRNA Journey: From Design to LNP-Ready Molecules for Research Discover an optimized end-to-end workflow for producing high-quality IVT mRNA for research applications.
01.21.26 -- Biology, Specificity, And The Rules Of RNA Business Strategy In 2026
Here, in part 3 of this outlook series, we continue our forward-looking conversation with Signify Bio CBO, Renee Williams, who shares why she hopes 2026 is the year we “focus in” on three important factors — namely our biology, our platforms, and our IP — and what this looks like/means strategically.
01.20.26 -- 2025 GLP-1 Impacts Tell Us About CDMOs In 2026
Outsourced Pharma Capabilities Update – Fill/Finish This event offers short, interactive digital presentations from leading CDMOs showcasing their capabilities, facilities, and available capacity for biopharma development and fill-finish manufacturing. Attendees can explore sterile filling, lyophilization, and packaging technologies, and ask questions live. Open to pharma and biotech professionals, industry consultants, investment firms, and CDMO sponsors seeking manufacturing solutions.
01.06.26 -- To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
The choice of delivery dictates the complexity of manufacturing, which in turn determines the eventual cost and accessibility of the therapy.
12.23.25 -- Strained Manufacturing, Complexity Stymie In Vivo Progress
The 2026 ISPE Facilities of the Future Conference will provide actionable insights and real-world case study examples addressing key industry challenges and opportunities, from best practices in facility design, digital transformation, and emerging technologies, to sustainability initiatives, workforce development, and compliance-related considerations. Gather innovative ideas on how to align your business priorities with forward-looking trends and prepare for the future. LEARN MORE.
12.16.25 -- The Top 10 Nations Redrawing The Outsourcing Map
Foreign Trade Zones (FTZs) offer a powerful way to reduce costs and improve operational agility for companies importing goods and manufacturing in the U.S. By deferring, reducing, or eliminating tariffs, businesses can optimize cash flow and avoid unnecessary delays. Duties are only paid when finished products enter the U.S. market, and if those products are exported globally, no U.S. duties apply. Click here to explore how FTZs can strengthen your supply chain and reduce costs.
12.15.25 -- Strained Manufacturing, Complexity Stymie In Vivo Progress
The 2026 ISPE Facilities of the Future Conference will provide actionable insights and real-world case study examples addressing key industry challenges and opportunities, from best practices in facility design, digital transformation, and emerging technologies, to sustainability initiatives, workforce development, and compliance-related considerations. Gather innovative ideas on how to align your business priorities with forward-looking trends and prepare for the future.
12.13.25 -- Bioprocess Online Best Of November
NOVEMBER'S BEST FEATURED EDITORIAL An End-To-End Automated HTP Platform For Cell Line Optimization Bristol Myers Squibb's high-throughput stable CHO platform produces high-titer, high-quality material in a fraction of the conventional timeline. Sensitive Critical Starting Materials Need A 'Just-In-Data' Approach Here's a blueprint for transforming the fragmented, high-risk interface between vector and cell therapy platforms into a unified, predictable, and compliant system.
12.05.25 -- Sensitive Critical Starting Materials Need A 'Just-In-Data' Approach
Join us for this Cell & Gene Live when Erin Harris, Chief Editor of Cell & Gene welcomes Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences at Accenture, and Michael Blackton MBA, VP, Manufacturing and Supply at Ocugen to unpack what CGT developers need to know about efficient, compliant dual- or multi-modal manufacturing even when production is outsourced. Registration is free thanks to support from Ecolab Life Sciences.
To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
By Victor Lien In vivo gene editing is positioned to fundamentally reshape the treatment of cancer, moving beyond conventional chemotherapy and radiation to enable direct, precise modifications of a patient’s DNA of the target cells of the organs. This approach eliminates the complex, time-consuming steps of ex vivo manipulation, which requires cell extraction, laboratory modification, and reinfusion, such as autologous cell therapy.
Strained Manufacturing, Complexity Stymie In Vivo Progress
By Victor Lien The scientific hurdles of delivery are not isolated from the realities of manufacturing; they directly dictate the processes, infrastructure, and timelines required to bring in vivo gene editing therapies to patients. Each delivery platform introduces unique manufacturing constraints that translate biological risk into operational bottlenecks.
To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
By Victor Lien In vivo gene editing is positioned to fundamentally reshape the treatment of cancer, moving beyond conventional chemotherapy and radiation to enable direct, precise modifications of a patient’s DNA of the target cells of the organs. This approach eliminates the complex, time-consuming steps of ex vivo manipulation, which requires cell extraction, laboratory modification, and reinfusion, such as autologous cell therapy.
To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
By Victor Lien In vivo gene editing is positioned to fundamentally reshape the treatment of cancer, moving beyond conventional chemotherapy and radiation to enable direct, precise modifications of a patient’s DNA of the target cells of the organs. This approach eliminates the complex, time-consuming steps of ex vivo manipulation, which requires cell extraction, laboratory modification, and reinfusion, such as autologous cell therapy.
Strained Manufacturing, Complexity Stymie In Vivo Progress
By Victor Lien The scientific hurdles of delivery are not isolated from the realities of manufacturing; they directly dictate the processes, infrastructure, and timelines required to bring in vivo gene editing therapies to patients. Each delivery platform introduces unique manufacturing constraints that translate biological risk into operational bottlenecks.
Strained Manufacturing, Complexity Stymie In Vivo Progress
By Victor Lien The scientific hurdles of delivery are not isolated from the realities of manufacturing; they directly dictate the processes, infrastructure, and timelines required to bring in vivo gene editing therapies to patients. Each delivery platform introduces unique manufacturing constraints that translate biological risk into operational bottlenecks.
11.24.25 -- Sensitive Critical Starting Materials Need A 'Just-In-Data' Approach
The push to lower biomanufacturing costs necessitates an increased focus on process efficiency and flexibility. Using perfusion technology in upstream processes can boost productivity and reduce costs compared to traditional methods. By maintaining high cell densities during cell expansion, perfusion minimizes equipment use, time, and resources while also lowering risks.
Sensitive Critical Starting Materials Need A 'Just-In-Data' Approach
Guest Column | November 14, 2025 By Victor Lien Cell and gene therapies are redefining the boundaries of modern medicine, offering transformative outcomes for patients with previously untreatable conditions. Yet these therapies challenge nearly every convention of traditional pharmaceutical manufacturing.
Sensitive Critical Starting Materials Need A 'Just-In-Data' Approach
Guest Column | November 13, 2025 By Victor Lien Cell and gene therapies are redefining the boundaries of modern medicine, offering transformative outcomes for patients with previously untreatable conditions. Yet these therapies challenge nearly every convention of traditional pharmaceutical manufacturing.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Victor
Contact Victor, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack